BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 22931650)

  • 21. Curcumin, a potent anti-tumor reagent, is a novel histone deacetylase inhibitor regulating B-NHL cell line Raji proliferation.
    Liu HL; Chen Y; Cui GH; Zhou JF
    Acta Pharmacol Sin; 2005 May; 26(5):603-9. PubMed ID: 15842781
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ganoderma immunomodulatory protein and chidamide down-regulate integrin-related signaling pathway result in migration inhibition and apoptosis induction.
    Lu CT; Leong PY; Hou TY; Huang SJ; Hsiao YP; Ko JL
    Phytomedicine; 2018 Dec; 51():39-47. PubMed ID: 30466626
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Histone deacetylase inhibitor chidamide regulates the Wnt/β-catenin pathway by MYCN/DKK3 in B-ALL.
    Zhao L; Lv C; Sun L; Li Q; Wang Y; Wu M; Wang Y; Guo Z; Bian S; Kong D; Lin L; Wang Y; Zhou J; Li Y
    Invest New Drugs; 2021 Aug; 39(4):961-970. PubMed ID: 33566253
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Modulation of histone acetylation and induction of apoptosis in SMMC-7721 cells by phenylhexyl isothiocyanate].
    Lai YD; Ma XD; Huang YQ; Xu XN; Wang XZ; Chiao DJ; Liu D
    Zhonghua Zhong Liu Za Zhi; 2010 Nov; 32(11):804-7. PubMed ID: 21223683
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chidamide and mitomycin C exert synergistic cytotoxic effects against bladder cancer cells in vitro and suppress tumor growth in a rat bladder cancer model.
    Wang SC; Yu CY; Wu YC; Chang YC; Chen SL; Sung WW
    Cancer Lett; 2022 Apr; 530():8-15. PubMed ID: 35033588
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cooperative effect of chidamide and chemotherapeutic drugs induce apoptosis by DNA damage accumulation and repair defects in acute myeloid leukemia stem and progenitor cells.
    Li Y; Wang Y; Zhou Y; Li J; Chen K; Zhang L; Deng M; Deng S; Li P; Xu B
    Clin Epigenetics; 2017; 9():83. PubMed ID: 28814980
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synergistic anticancer effect of a combination of chidamide and etoposide against NK/T cell lymphoma.
    Song W; Chen Z; Shi C; Gao Y; Feng X; Li H; Li Z; Zhang M
    Hematol Oncol; 2023 Apr; 41(2):257-266. PubMed ID: 34854108
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chidamide, a histone deacetylase inhibitor-based anticancer drug, effectively reactivates latent HIV-1 provirus.
    Yang W; Sun Z; Hua C; Wang Q; Xu W; Deng Q; Pan Y; Lu L; Jiang S
    Microbes Infect; 2018; 20(9-10):626-634. PubMed ID: 29126877
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Non-toxic dose chidamide synergistically enhances platinum-induced DNA damage responses and apoptosis in Non-Small-Cell lung cancer cells.
    Zhou Y; Pan DS; Shan S; Zhu JZ; Zhang K; Yue XP; Nie LP; Wan J; Lu XP; Zhang W; Ning ZQ
    Biomed Pharmacother; 2014 May; 68(4):483-91. PubMed ID: 24721323
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic effects of the novel subtype-selective histone deacetylase inhibitor chidamide on myeloma-associated bone disease.
    He J; Chen Q; Gu H; Chen J; Zhang E; Guo X; Huang X; Yan H; He D; Yang Y; Zhao Y; Wang G; He H; Yi Q; Cai Z
    Haematologica; 2018 Aug; 103(8):1369-1379. PubMed ID: 29773595
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chidamide combined with paclitaxel effectively reverses the expression of histone deacetylase in lung cancer.
    Zhang N; Sun P; Jin H; Yang Y; Zhao Q; Zhou L; Guo L; Yang X; Lu L
    Anticancer Drugs; 2020 Aug; 31(7):702-708. PubMed ID: 32701251
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synergistic antitumor effect of histone deacetylase inhibitor and Doxorubicin in peripheral T-cell lymphoma.
    Zhang H; Dong L; Chen Q; Kong L; Meng B; Wang H; Fu K; Wang X; Pan-Hammarström Q; Wang P; Wang X
    Leuk Res; 2017 May; 56():29-35. PubMed ID: 28171799
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A novel histone deacetylase inhibitor LT-548-133-1 induces apoptosis by inhibiting HDAC and interfering with microtubule assembly in MCF-7 cells.
    Xue J; Wu G; Ejaz U; Akhtar F; Wan X; Zhu Y; Geng A; Chen Y; He S
    Invest New Drugs; 2021 Oct; 39(5):1222-1231. PubMed ID: 33788074
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chidamide Inhibits Cell Proliferation via the PI3K/AKT Pathway in K562 Cells Based on Network Pharmacology and Experimental Validation.
    Liang S; Zhou X; Cai D; Rodrigues-Lima F; Wang L
    Curr Pharm Des; 2021; 27(26):2990-2998. PubMed ID: 34218775
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chidamide-induced ROS accumulation and miR-129-3p-dependent cell cycle arrest in non-small lung cancer cells.
    Wu YF; Ou CC; Chien PJ; Chang HY; Ko JL; Wang BY
    Phytomedicine; 2019 Mar; 56():94-102. PubMed ID: 30668358
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transcriptome Profiling Analysis Identifies LCP1 as a Contributor for Chidamide Resistance in Gastric Cancer.
    Bao W; Zhu Z; Gao Y; Chen J
    Pharm Res; 2022 May; 39(5):867-876. PubMed ID: 35578065
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epigenetic therapy with chidamide alone or combined with 5‑azacitidine exerts antitumour effects on acute myeloid leukaemia cells
    Li Z; Zhang J; Zhou M; Li JL; Qiu QC; Fu JH; Xue SL; Qiu HY
    Oncol Rep; 2022 Apr; 47(4):. PubMed ID: 35103292
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chidamide, a histone deacetylase inhibitor, induces growth arrest and apoptosis in multiple myeloma cells in a caspase-dependent manner.
    Yuan XG; Huang YR; Yu T; Jiang HW; Xu Y; Zhao XY
    Oncol Lett; 2019 Jul; 18(1):411-419. PubMed ID: 31289512
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Inhibitory effect of VPA on multiple myeloma U266 cell proliferation and regulation of histone acetylation].
    Zhu YF; Ye BG; Shen JZ; Lin CM; Lin FA; Shen SF; Xu CB
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Jun; 18(3):638-41. PubMed ID: 20561418
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chidamide and orelabrutinib synergistically induce cell cycle arrest and apoptosis in diffuse large B-cell lymphoma by regulating the PI3K/AKT/mTOR pathway.
    Wu C; Chen S; Wu Z; Xue J; Zhang W; Wang S; Xindong Zhao ; Wu S
    J Cancer Res Clin Oncol; 2024 Feb; 150(2):98. PubMed ID: 38381215
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.